1st Quarter Results | 25-Apr-2024 | 07:00 | RNS |
Result of AGM | 11-Apr-2024 | 17:30 | RNS |
AstraZeneca increases 2024 dividend by 7% | 11-Apr-2024 | 07:00 | RNS |
Enhertu approved in US for HER2+ solid tumours | 08-Apr-2024 | 07:00 | RNS |
Imfinzi improved OS & PFS in limited-stage SCLC | 05-Apr-2024 | 07:00 | RNS |
Total Voting Rights | 02-Apr-2024 | 15:00 | RNS |
Voydeya approved in US | 02-Apr-2024 | 07:05 | RNS |
FDA accepts Dato-DXd BLA for breast cancer | 02-Apr-2024 | 07:00 | RNS |
Ultomiris approved in the US for NMOSD | 25-Mar-2024 | 07:00 | RNS |
AstraZeneca to acquire Fusion | 19-Mar-2024 | 07:00 | RNS |
AstraZeneca to acquire Amolyt | 14-Mar-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 12-Mar-2024 | 11:00 | RNS |
Notice of AGM | 07-Mar-2024 | 11:00 | RNS |
Director/PDMR Shareholding | 06-Mar-2024 | 15:05 | RNS |
Director/PDMR Shareholding | 06-Mar-2024 | 15:00 | RNS |
Currency | UK Pounds |
Share Price | 11,962.00p |
Change Today | 610.00p |
% Change | 5.37 % |
52 Week High | 12,086.00 |
52 Week Low | 9,501.00 |
Volume | 1,030,476 |
Shares Issued | 1,550.22m |
Market Cap | £185,438m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 13 |
Neutral | 6 |
Sell | 0 |
Strong Sell | 1 |
Total | 28 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 22-Feb-24 | 10-Aug-23 |
Paid | 25-Mar-24 | 11-Sep-23 |
Amount | 197.00¢ | 93.00¢ |
Time | Volume / Share Price |
12:02 | 38 @ 11,962.00p |
12:02 | 21 @ 11,962.00p |
12:01 | 2 @ 11,962.00p |
12:01 | 13 @ 11,964.00p |
12:01 | 31 @ 11,964.00p |
You are here: research